Publications by authors named "W L Bor"
Article Synopsis
- Major or life-threatening bleeding and stroke are complications that can occur after transcatheter aortic valve implantation (TAVI), impacting both mortality and quality of life (QoL).
- Major bleeding increases the risk of death significantly, while minor bleeding does not affect mortality; however, both types of bleeding and stroke lead to lower mental QoL scores.
- The study highlights that monitoring these complications is essential, as they correlate with poorer mental well-being in patients during the first year post-TAVI.
Article Synopsis
- * In a trial with 858 patients, results showed no significant difference in major complications between those who continued anticoagulation (16.5% experienced primary outcomes) and those who interrupted it (14.8%).
- * Continuation of anticoagulation led to higher incidences of major bleeding (31.1% vs. 21.3%), suggesting that interrupting anticoagulation is safer in this patient population undergoing TAVI.
Background: Acute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF).
Aims: We aimed to compare the risk of major adverse cardiovascular events (MACE) in ACS patients presenting with known, newly diagnosed, or no AF.
Methods: In our multicentre, prospective registry study, we included patients with confirmed ACS.
Objectives: This study aimed to determine whether family poverty over the early childhood, adolescent, and adult periods of the life course independently predicts experiences of intimate partner violence (IPV) in adulthood.
Study Design: This was a birth cohort study in Brisbane, Australia, with pregnant women recruited at their first booking-in visit and their children, followed up to 30 and 40 years of age.
Methods: Family income was obtained from the mother when the child was 6 months, 5 and 14 years of age.
Article Synopsis
- The optimal management of patients with atrial fibrillation (AF) requiring oral anticoagulation (OAC) during percutaneous coronary intervention (PCI) is debated, with current guidelines suggesting a temporary triple therapy regimen that includes aspirin, which raises bleeding risks.
- A new study, the WOEST-3 trial, seeks to compare a 30-day dual antiplatelet therapy (DAPT) strategy that temporarily omits OAC against guideline-directed therapy post-PCI for AF patients, aiming to reduce bleeding without sacrificing efficacy.
- With a sample of 2,000 patients, the trial will evaluate the rates of major bleeding and adverse ischemic events, making it the first randomized controlled trial to explore the omission of OAC